Amylyx Pharmaceuticals, Inc. $AMLX Shares Sold by Maven Securities LTD

Maven Securities LTD reduced its holdings in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 50.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,000 shares of the company’s stock after selling 25,000 shares during the quarter. Maven Securities LTD’s holdings in Amylyx Pharmaceuticals were worth $449,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in AMLX. KBC Group NV bought a new stake in shares of Amylyx Pharmaceuticals in the first quarter worth $26,000. Meeder Asset Management Inc. bought a new position in Amylyx Pharmaceuticals during the 4th quarter valued at $25,000. State of Wyoming bought a new position in Amylyx Pharmaceuticals during the 2nd quarter valued at $40,000. Caitong International Asset Management Co. Ltd grew its holdings in Amylyx Pharmaceuticals by 954.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company’s stock worth $47,000 after acquiring an additional 3,493 shares in the last quarter. Finally, California State Teachers Retirement System acquired a new position in Amylyx Pharmaceuticals during the 2nd quarter worth $28,000. Institutional investors and hedge funds own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Price Performance

Amylyx Pharmaceuticals stock opened at $33.88 on Wednesday. Amylyx Pharmaceuticals, Inc. has a 12 month low of $10.37 and a 12 month high of $41.14. The company has a fifty day moving average price of $24.86 and a two-hundred day moving average price of $18.49. The company has a market cap of $3.77 billion, a PE ratio of -23.69 and a beta of -0.13.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). Equities research analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -1.48 earnings per share for the current year.

Insider Activity at Amylyx Pharmaceuticals

In related news, insider Gina Mazzariello sold 15,000 shares of the business’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $18.32, for a total transaction of $274,800.00. Following the completion of the sale, the insider owned 194,090 shares of the company’s stock, valued at $3,555,728.80. This represents a 7.17% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 10.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Wednesday, August 5th. Robert W. Baird increased their price target on shares of Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 19th. Guggenheim lifted their price target on Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the stock a “buy” rating in a research note on Thursday, August 27th. HC Wainwright upped their price objective on Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. Finally, Wolfe Research upgraded Amylyx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 17th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amylyx Pharmaceuticals has an average rating of “Buy” and an average price target of $36.50.

About Amylyx Pharmaceuticals